Dexcom (DXCM) CFO granted 48,774 RSUs, 18,950 shares withheld for taxes

Rhea-AI Filing Summary

Dexcom Inc. EVP and CFO Sylvain Jereme reported a compensation-related equity transaction. He received a grant of 48,774 restricted stock units (RSUs) that will vest in three equal annual installments from the March 8, 2026 grant date. On the same date, 18,950 shares of common stock at $68.10 per share were withheld by Dexcom to satisfy tax obligations from RSU settlements, which the company states does not represent a sale by him. Following these transactions, he directly owns 153,292 Dexcom shares, including 92,794 unvested RSUs with various grant dates vesting through March 8, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sylvain Jereme M

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		A		48,774(1)	A	$0	172,242	D
Common Stock	03/08/2026		F		18,950(2)	D	$68.1	153,292(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 92,794 unvested RSUs, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 261 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Remarks:

	/s/ Jereme M. Sylvain	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dexcom (DXCM) CFO Sylvain Jereme receive in this Form 4 filing?

Dexcom EVP and CFO Sylvain Jereme received a grant of 48,774 restricted stock units. These RSUs vest in three equal annual installments from March 8, 2026, giving him a contingent right to receive one Dexcom common share for each vested RSU.

Why were 18,950 Dexcom (DXCM) shares disposed of in this Form 4?

The 18,950 Dexcom shares were withheld by the company to cover tax withholding and remittance obligations. The filing specifies this withholding relates to RSU net settlement and does not represent an open-market sale by Sylvain Jereme.

How many Dexcom (DXCM) shares does the CFO hold after these transactions?

After these transactions, Sylvain Jereme directly holds 153,292 Dexcom common shares. This figure includes both vested stock and 92,794 unvested RSUs that are scheduled to vest between March 8, 2024 and March 8, 2029.

How are the newly granted Dexcom (DXCM) RSUs scheduled to vest?

The 48,774 RSUs granted on March 8, 2026 vest in three equal annual installments. Each year on the anniversary of the grant date, one-third of the RSUs is scheduled to convert into Dexcom common shares, subject to the applicable vesting conditions.

What other unvested Dexcom (DXCM) RSUs are included in the CFO’s holdings?

The 92,794 unvested RSUs include 48,774 granted March 8, 2026; 23,937 and 11,399 granted March 8, 2025; and 8,684 granted March 8, 2024. These grants are scheduled to vest through dates ranging from March 8, 2027 to March 8, 2029.

Does this Dexcom (DXCM) Form 4 indicate an open-market sale by the CFO?

The Form 4 states the 18,950-share disposition was tax withholding for RSU settlement, not an open-market sale. Shares were withheld by Dexcom to meet tax obligations, so the filing does not show discretionary selling activity by the CFO.